Navigation Links
Escalon(R) Reports Second Quarter Fiscal 2008 Results
Date:2/14/2008

0 7,636,740 14,388,351 14,804,900

Costs and expenses:

Cost of goods sold 3,951,607 3,878,214 7,874,193 7,508,594

Research and development 876,750 1,080,950 1,800,111 1,794,555

Marketing, general and

administrative 3,372,353 3,144,611 6,312,261 6,700,511

Total costs and

expenses 8,200,710 8,103,775 15,986,565 16,003,660

Loss from operations (705,630) (467,035) (1,598,214) (1,198,760)

Other (expense) and

income:

Equity in Ocular

Telehealth Management,

LLC (16,611) (12,155) (50,722) (30,698)

Interest income 85,391 13,498 187,088 58,934

Interest expense (2,496) (5,654) (6,289) (14,939)

Total other income 66,284 (4,311) 130,077 13,297

Net (loss) before taxes (639,346) (471,346) (1,468,137) (1,185,463)

Benefit from income taxes - (1,243) 0 (1,243)

Net (loss) $(639,346) $(470,103) $(1,468,137) $(1,184,220)

Basic net (loss) per

share $(0.10) $(0.07) $(0.23) $(0.19)

Diluted net (loss) per

share $(0.10) $(0.07) $(0.23) $(0.19)

Weighted average shares

- basic 6,389,315 6,347,972 6,388,701 6,346,315

Weighted average shares

- diluted 6,389,315 6,347,972 6,388,701 6,346,315

SELECTED BALANCE SHEET DATA:

December 31, June 30,

2007 2007

Cash, cash equivalents and Investments $7,527,023 $8,879,462

Total current assets $20,063,637 $21,763,012

Total assets
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System
3. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... OncoTAb, Inc., a University ... announced that Pinku Mukherjee, Ph.D. has received the ... Governors’ highest faculty honor. Mukherjee received the award, which ... her innovative research and development of cancer diagnostics and ... crowning moment in my scientific career,” said Mukherjee, OncoTAb ...
(Date:5/1/2015)... DIEGO , May 1, 2015 ... company engaged in the development of biosimilar therapeutics ... announced today that its first quarter 2015 financial ... 2015, before the open of market. At 8:30 am ... call to discuss the financial results and provide ...
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme ... patients refractory to conventional therapy.  Chronic gout that is ... failed to normalize serum uric acid and whose signs ...
... Calif., Sept. 14 The launch of IntriMed ... Innovation Center in Oxnard, Calif. were announced today ... design and manufacture of ultra-precise components for the ... 23 year heritage of engineering innovation, IntriMed ( ...
... (Nasdaq: BSTC ), a biopharmaceutical company developing ... President, Tom Wegman, will present at the upcoming UBS ... at 7:30am ET at the Grand Hyatt New York ... of the presentation can be accessed under "Calendar of ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 2IntriMed Technologies Launched to Address Challenges Faced by Medical Device Manufacturers 3
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... why premature birth is a growing problem in the United ... that pre-pregnancy depressive mood appears to be a risk factor ... however, have nearly two times the odds of having a ... a University of Washington assistant professor of social work and ...
... pregnant women hinders brain development in their children ... thyroid hormone levels in the fetal brain, a ... Wednesday at The Endocrine Society,s 91st Annual Meeting ... moderate drinking during pregnancycan cause neurodevelopmental disorders, such ...
... , This release is available in ... this is particularly true for cancer medicine. The ... further increased if research results are swiftly transferred from ... research transfer, also called translational research, will now be ...
Cached Biology News:Pre-pregnancy depressed mood may heighten risk for premature birth 2Pre-pregnancy depressed mood may heighten risk for premature birth 3Specific genetic cause of fetal alcohol-related developmental disorders found 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 2German Research Minister Schavan: 'Rapid knowledge transfer can safe lives' 3
Human ABCG2 MAb (Clone 5D3)...
... The Beacon 2000 One-Step FP ... characteristic high and low fluorescence polarization ... users of the Beacon 2000 System. ... the polarization values generated by their ...
...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
Biology Products: